 |
|
|
| |
NGM282 Maintains a Durable Off-Treatment Response on Hepatic Steatosis, Inflammation and Fibrogenesis in Patients with Biopsy-Confirmed Nonalcoholic Steatohepatitis: Results of a Multi-Center Phase 2 Dose-Finding Study
|
| |
| |
Reported by Jules Levin
AASLD 2018 Nov 9-13 SF
Angelo H. Paredes1, James F. Trotter2, Mustafa R. Bashir3, Guy W. Neff 4, Manal F. Abdelmalek5, Grisell Ortiz-Lasanta6, Mark J. Jaros7, Bryan A. Baxter8, Lei Ling8, Stephen J. Rossi8, Alex M. DePaoli8, Stephen A. Harrison9
|
| |
|
|
|
|
|
